The Rockefeller University

Washington State University

Other

Atairgin Technologies, Inc.

Lpl Technologies, Inc.

Michael K Skinner

Nathaniel Heintz

Jeff A Parrott

Jodi L Johnson

John Gubbay

Carlos M Guerrero-Bosagna

Jaideep Chaudhary

CpG densities and sequence motifs that are characteristic of regions of DNA associated with epimutations and control of epimutations are provided. Such regions include, within approximately 400 (or fewer) base pairs, at least one, usually two, and preferably all three of the following features: i) a CpG density of 15% or less; ii) the presence of the sequence motif ATTTGTTTTTTCTTTTnT (SEQ ID NO: 1) where n is A, T, C or G, and statistically relevant variants thereof; and iii) the presence of the sequence motif GGGGGnGGGG (SEQ ID NO: 2), where n is A, T, C or G, and statistically relevant variants thereof.

Genomic features associated with epigenetic control regions and transgenerational inheritance of epimutations

The present invention provides methods for detecting epigenetic, multigenerational DNA alterations caused by toxicants such as endocrine disruptor agents in a subject. The practice of the present invention can be used to diagnose and/or treat a subject having the identified DNA alterations by developing therapeutics, to prevent or delay the onset of associated diseases and/or dysfunctions.

Methods for diagnosing epigenetic, transgenerational effects of environmental toxicants on mammalian germ-lines and treating associated diseases

The present invention relates to modified cells carrying a heterologous gene sequence encoding a protein, such as an Inhibitor of differentiation (Id) gene sequence that binds a basic helix-loop-helix (bHLH) protein to inhibit cell growth, differentiation and/or tumorigenesis of the modified cells. The modified cells are differentiated, proliferate and do not become tumorigenic when grafted into a recipient subject. Additionally, the modified cells produce a factor or factors that enhance the viability of co-grafted organs, tissues or cells. Thus, the modified cells are useful for testing agents for effects on the cells, for co-grafting with transplant organs, tissues or cells. The modified cells are also useful for enhancing the viability of thawing cells that have been cryo-preserved. In one embodiment, the modified cells are modified Sertoli cells.

Modified cells expressing a protein that modulates activity of bHLH proteins, and uses thereof

The present invention relates to non-radioactive enzymatic methods for detecting Sphingosine-1-Phosphate (S1P) in biological fluids. The present invention further relates to a method of detecting the presence of cancer in a patient by the use of these and other methods of detecting S1P in biological samples from a patient.

Method for detecting sphingosine-1-phosphate (S1P) for cancer detection

The present invention relates to non-radioactive enzymatic methods for detecting Sphingosine-1-Phosphate (S1P) in biological fluids. The present invention further relates to a method of detecting the presence of cancer in a patient by the use of these and other methods of detecting (S1P) in biological samples from a patient.

Enzyme method for detecting sphingosine-1-phosphate (S1P)

The present invention identifies cDNA collections enriched in genes regulated in prostate homeostasis, prostate regression, and in genes regulated in programmed cell death. These novel cDNA collections provide cDNAs that encode proteins that are either unique to general programmed cell death or unique to prostate regression. These transcripts can be used as markers to screen, monitor and/or to diagnose diseased conditions including prostate cancer. In addition, these cDNA collections can be used in methods of designing novel therapeutic agents useful for treating prostate cancer. Methods of making these collections through subtraction hybridization are described.

CDNA collections encoding proteins regulated during programmed cell

The present invention identifies cDNA collections enriched in genes regulated in prostate homeostasis, prostate regression, and in genes regulated in programmed cell death. These novel cDNA collections provide cDNAs that encode proteins that are either unique to general programmed cell death or unique to prostate regression. These transcripts can be used as markers to monitor and/or to diagnose diseased conditions. Methods of making these collections through subtraction hybridization are described.

Growing community of inventors

Pullman, WA, United States of America

Michael K Skinner